Home›Lincomycin Hydrochloride

Lincomycin Hydrochloride

Also known as: Lincomycin

Route: Intramuscular, Intravenous, Subconjunctival

Check Lincomycin Hydrochloride Interactions →

2 interactions on record⛔ Black Box Warning

Lincomycin Hydrochloride has 2 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Adrenergic Blockers, Lincomycin. Patients taking Lincomycin Hydrochloride should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 2
Moderate: 2

Moderate (2)

Lincomycin Hydrochloride + Adrenergic Blockers— Lincomycin has neuromuscular blocking properties that may enhance the action of neuromuscular blocking agents; use with …
Lincomycin Hydrochloride + Lincomycin— Drug Interactions Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of oth…

Lincomycin Hydrochloride + Adrenergic Blockers🟡Moderate

Lincomycin has neuromuscular blocking properties that may enhance the action of neuromuscular blocking agents; use with caution in patients receiving such agents.

Lincomycin Hydrochloride + Lincomycin🟡Moderate

Drug Interactions Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents; therefore, it should be used with caution in patients receiving such agents.

⛔ FDA Black Box Warning

WARNING Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including lincomycin injection and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because lincomycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. diffficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated.

Contraindications

CONTRAINDICATIONS Lincomycin injection is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin.

Pregnancy & Breastfeeding

Pregnancy There are no adequate and well-controlled studies in pregnant women. Lincomycin injection Sterile Solution contains benzyl alcohol as a preservative. Benzyl alcohol can cross the placenta (see WARNINGS ) . Lincomycin injection should be used during pregnancy only if clearly needed. Teratogenic Effects: In a study with 60 pregnant women, cord serum concentrations were approximately 25% of the maternal serum concentrations, indicating that lincomycin crosses the placenta, and no substantial accumulation occurred in the amniotic fluid. Experience with 345 obstetrical patients receiving lincomycin injection revealed no ill effects related to pregnancy. There was no evidence of teratogenicity when lincomycin was administered in diet to pregnant Sprague Dawley rats during the period of major organogenesis at doses up to 5000 mg/kg (approximately 6 times the maximum recommended human dose [MRHD], respectively, based on body surface area comparison). Nonteratogenic Effects: Reproduction studies performed in rats administered oral lincomycin in diet for 2 weeks prior to mating, throughout pregnancy and lactation, revealed no adverse effects on survival of offspring from birth to weaning at doses up to 1000 mg/kg (1.2 times the MRHD based on body surface area comparison) up to 2 generations.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.